ClinicalTrials.gg
CompletedNCT02489968Updated Sep 6, 2018Results posted

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus

A Phase 3 interventional study of empagliflozin 10 mg + linagliptin 5 mg and empagliflozin 10 mg in Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Completed at 83 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2018-09-06.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
880
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 — 18 open to participants now, 19 under way, 1 of them phase 3. empagliflozin · Diabetes Mellitus, Type 2.

Enrollment
15th of 130
880 · median 79
Started
2015
with 4 others
Phase 3
28 of 130
1 open now
Registered
33rd of 130
by date
Lead sponsor
37 of 130
Boehringer Ingelheim

Among the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, this one is the 15th largest by enrollment, is one of 5 that started in 2015, is one of 28 in phase 3, and was the 33rd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

18 of the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 are open now, in 10 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About empagliflozin

empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Two independent study parts (i.e. Part A and Part B) are included in this trial. Part A will evaluate empagliflozin 10 mg + linagliptin and Part B will evaluate empagliflozin 25 mg + linagliptin. All analyses will be carried out separately for these study parts. The objective of Part A is to investigate the efficacy, safety and tolerability of the fixed dose combination (FDC) of empagliflozin 10 mg / linagliptin 5 mg compared with empagliflozin 10 mg plus FDC matching placebo administered orally once daily for 24 weeks in Japanese patients with T2DM (Type 2 Diabetes Mellitus) who have insufficient glycaemic control after 16 weeks of treatment with empagliflozin 10 mg alone once daily. The study is designed to show superiority of the FDC of empagliflozin 10 mg / linagliptin 5 mg over empagliflozin 10 mg plus FDC matching placebo after 24 weeks of treatment. The objective of Part B is to investigate the efficacy, safety and tolerability of the FDC of empagliflozin 25 mg / linagliptin 5 mg compared with empagliflozin 25 mg plus FDC matching placebo administered orally once daily for 24 weeks in Japanese patients with T2DM who have insufficient glycaemic control after 16 weeks of treatment with empagliflozin 25 mg alone once daily. The study is designed to show superiority of the FDC of empagliflozin 25 mg / linagliptin 5 mg over empagliflozin 25 mg plus FDC matching placebo after 24 weeks of treatment. The 24 week treatment period will be followed by a 28 week extension treatment period to evaluate further efficacy and safety up to 52 weeks.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of type 2 diabetes prior to
  • Male and female patients on diet and exercise regimen for at least 12 weeks prior to informed consent who are:

    • drug-naïve, defined as no antidiabetic drugs for at least 12 weeks prior to informed consent or,
    • pre-treated with one oral antidiabetic drug (for sulfonylurea, with up to half of the maximum approved dose) on stable dosage for at least 12 weeks prior to the informed consent (for thiazolidinedione, therapy has to be unchanged for at least 18 weeks prior to the informed consent). Individual antidiabetic drug will have to be discontinued at Visit 1.
  • (HbA1c) at Visit 1 (screening)

    • for patients without antidiabetic therapy : HbA1c >=8.0 to =\<10.5%
    • for patients with one oral antidiabetic drug : HbA1c >=7.5 to =\<10.5%
  • HbA1c >=7.5 to =\<10.0% at Visit 4 for randomisation into the double blind treatment period

Exclusion criteria

Exclusion criteria:

  • Uncontrolled hyperglycaemia with a glucose level >270 mg/dL (>15.0 mmol/L) during the open label stabilisation period and placebo run in period
  • Impaired renal function, defined as estimated (eGFR) \<45 mL/min/1.73m2 (modification of diet in renal disease (MDRD) formula)
  • Acute coronary syndrome, stroke or (TIA) within 12 weeks prior to
  • Indication of liver disease, defined by serum levels of either (ALT), aspartate transaminase (AST), or alkaline phosphatase (ALP) above 3 x (ULN)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
880 participants (actual)

Study arms

  • Experimental
    empagliflozin 10 mg + linagliptin 5 mg

    patient to receive a tablet containing low dose empagliflozin and linagliptin once daily

    Drug: empagliflozin 10 mg + linagliptin 5 mg

  • Experimental
    empagliflozin 10 mg

    patient to receive a tablet containing low dose empagliflozin once daily

    Drug: empagliflozin 10 mg · Drug: Placebo

  • Experimental
    empagliflozin 25 mg + linagliptin 5 mg

    patient to receive a tablet containing high dose empagliflozin and linagliptin once daily

    Drug: empagliflozin 25 mg + linagliptin 5 mg

  • Experimental
    empagliflozin 25 mg

    patients to receive a tablet containing high dose empagliflozin once daily

    Drug: empagliflozin 25 mg · Drug: Placebo

Interventions

  • Drugempagliflozin 10 mg + linagliptin 5 mg

    Drug page: Empagliflozin

    empagliflozin low dose + linagliptin once daily

  • empagliflozin low dose once daily

  • Drugempagliflozin 25 mg + linagliptin 5 mg

    Drug page: Empagliflozin

    empagliflozin high dose + linagliptin once daily

  • empagliflozin high dose once daily

  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Change in Glycated Haemoglobin A1c (HbA1c) (%) From Baseline After 24 Weeks of Treatment

    Change from baseline in HbA1c (%) after 24 weeks of treatment with double-blind trial medication. Change was calculated as: HbA1c value at 24-week - HbA1c value at baseline, for each patient. Baseline was defined as the last observation before the first intake of double-blind randomised trial medication. Statistical analysis presented is based on a restricted maximum likelihood (REML)-based mixed model repeated measures (MMRM) approach. Full Analysis Set (Observed Cases) \[FAS (OC)\]: This analysis set consisted of all patients who were randomised and treated with at least 1 dose of trial drug during the double-blind part of the trial and who had a baseline HbA1c assessment and at least 1 on-treatment HbA1c assessment during the 24-week double-blind part of the trial. Observed cases analysis included only the available data that were observed while patients were on treatment, i.e., excluding the missing data.

    Time frame: Baseline and 24 week

07

Results

Posted Sep 6, 2018

Participant flow

Open-label Treatment Period
Participant flow — Open-label Treatment Period
MilestoneEmpagliflozin 10 mg OLEmpagliflozin 25 mg OLEmpagliflozin 10 mg + Linagliptin 5 mgEmpagliflozin 10 mg + PlaceboEmpagliflozin 25 mg + Linagliptin 5 mgEmpagliflozin 25 mg + Placebo
Started4394400000
Completed2152320000
Not completed2242080000
Withdrew: Adverse event1470000
Withdrew: Protocol violation220000
Withdrew: Lost to follow-up030000
Withdrew: Withdrawal by subject470000
Withdrew: Other than specified above2041890000
Double-blind Treatment Period
Participant flow — Double-blind Treatment Period
MilestoneEmpagliflozin 10 mg OLEmpagliflozin 25 mg OLEmpagliflozin 10 mg + Linagliptin 5 mgEmpagliflozin 10 mg + PlaceboEmpagliflozin 25 mg + Linagliptin 5 mgEmpagliflozin 25 mg + Placebo
Started00107108116116
Completed00105100110108
Not completed002868
Withdrew: Adverse event002645
Withdrew: Protocol violation000011
Withdrew: Withdrawal by subject000202
Withdrew: Other than specified above000010

Outcome measures

PrimaryChange in Glycated Haemoglobin A1c (HbA1c) (%) From Baseline After 24 Weeks of Treatment

Change from baseline in HbA1c (%) after 24 weeks of treatment with double-blind trial medication. Change was calculated as: HbA1c value at 24-week - HbA1c value at baseline, for each patient. Baseline was defined as the last observation before the first intake of double-blind randomised trial medication. Statistical analysis presented is based on a restricted maximum likelihood (REML)-based mixed model repeated measures (MMRM) approach. Full Analysis Set (Observed Cases) \[FAS (OC)\]: This analysis set consisted of all patients who were randomised and treated with at least 1 dose of trial drug during the double-blind part of the trial and who had a baseline HbA1c assessment and at least 1 on-treatment HbA1c assessment during the 24-week double-blind part of the trial. Observed cases analysis included only the available data that were observed while patients were on treatment, i.e., excluding the missing data.

Time frame:
Baseline and 24 week
Reported as:
Least squares mean · Percentage (%)
Change in Glycated Haemoglobin A1c (HbA1c) (%) From Baseline After 24 Weeks of Treatment
Percentage (%)Empagliflozin 10 mg + Linagliptin 5 mgEmpagliflozin 10 mg + PlaceboEmpagliflozin 25 mg + Linagliptin 5 mgEmpagliflozin 25 mg + Placebo
Change in Glycated Haemoglobin A1c (HbA1c) (%) From Baseline After 24 Weeks of Treatment-0.94 ± 0.05-0.12 ± 0.06-0.91 ± 0.05-0.33 ± 0.05
Statistical analysis
  • Empagliflozin 10 mg + Linagliptin 5 mg vs Empagliflozin 10 mg + Placebo · REML based MMRM · p = <0.0001 · Adjusted mean difference: -0.82 · 95% CI -0.97 to -0.67Adjusted mean difference: Change in HbA1c in (empagliflozin 10 mg + linagliptin 5 mg) - change in HbA1c in (empagliflozin 10 mg + placebo)
  • Empagliflozin 25 mg + Linagliptin 5 mg vs Empagliflozin 25 mg + Placebo · REML based MMRM · p = <0.0001 · Adjusted mean difference: -0.59 · 95% CI -0.73 to -0.45Adjusted mean difference: Change in HbA1c in (empagliflozin 25 mg + linagliptin 5 mg) - change in HbA1c in (empagliflozin 25 mg + placebo)

Adverse events

Collected over From first drug administration till two weeks after last drug administration; up to 72 weeks (including 16 weeks open-label, 2 weeks run-in period and 52 weeks double-blind treatment period).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Empagliflozin 25 mg + Linagliptin 5 mg—6/116 (5.2%)54/116 (46.6%)
Empagliflozin 10 mg + Linagliptin 5 mg—1/107 (0.9%)24/107 (22.4%)
Empagliflozin 25 mg + Placebo—8/116 (6.9%)51/116 (44%)
Empagliflozin 10 mg + Placebo—4/108 (3.7%)36/108 (33.3%)
Empagliflozin 25 mg OL—11/440 (2.5%)131/440 (29.8%)
Empagliflozin 10 mg OL—9/439 (2.1%)120/439 (27.3%)
Most frequent serious events
Showing 10 of 44
Most frequent serious events
EventEmpagliflozin 25 mg + Linagliptin 5 mgEmpagliflozin 10 mg + Linagliptin 5 mgEmpagliflozin 25 mg + PlaceboEmpagliflozin 10 mg + PlaceboEmpagliflozin 25 mg OLEmpagliflozin 10 mg OL
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1161/1071/1160/1080/4400/439
SepsisInfections and infestations0/1160/1070/1161/1080/4400/439
Disseminated intravascular coagulationBlood and lymphatic system disorders0/1160/1070/1161/1080/4400/439
Acute myocardial infarctionCardiac disorders0/1160/1070/1161/1080/4400/439
Atrial flutterCardiac disorders0/1160/1070/1161/1080/4400/439
CholangitisHepatobiliary disorders0/1160/1070/1161/1080/4400/439
Femur fractureInjury, poisoning and procedural complications0/1160/1070/1161/1080/4400/439
Metastases to boneNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1160/1071/1160/1080/4400/439
Metastases to lymph nodesNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1160/1071/1160/1080/4400/439
Anaphylactic shockImmune system disorders1/1160/1070/1160/1080/4400/439
Most frequent other events
Most frequent other events
EventEmpagliflozin 25 mg + Linagliptin 5 mgEmpagliflozin 10 mg + Linagliptin 5 mgEmpagliflozin 25 mg + PlaceboEmpagliflozin 10 mg + PlaceboEmpagliflozin 25 mg OLEmpagliflozin 10 mg OL
Viral upper respiratory tract infectionInfections and infestations31/11616/10734/11624/10846/44047/439
Blood ketone body increasedInvestigations16/1162/1079/11611/10840/44026/439
PollakiuriaRenal and urinary disorders0/1160/1070/1161/10835/44030/439
Weight decreasedInvestigations2/1160/1077/1161/10810/44016/439
Back painMusculoskeletal and connective tissue disorders7/1163/1072/1163/1085/4402/439
PeriodontitisInfections and infestations3/1160/1076/1161/1082/4402/439
ConstipationGastrointestinal disorders5/1162/1076/1160/10811/44010/439
ContusionInjury, poisoning and procedural complications4/1163/1076/1161/1083/4404/439

Baseline characteristics

Open-label full analysis set (OLFAS) consisted of all patients in the open-label period who received at least 1 dose of open-label study drug during the trial and had a pre-treatment Glycated haemoglobin A1c (HbA1c) assessment and at least 1 on-treatment HbA1c assessment during the open-label part of the trial.

Age, Continuous
Age, Continuous(Years)Empagliflozin 10 mg OLEmpagliflozin 25 mg OLTotal
Mean56.8 ± 10.257.5 ± 10.057.2 ± 10.1
Sex: Female, Male
Sex: Female, Male(Participants)Empagliflozin 10 mg OLEmpagliflozin 25 mg OLTotal
Female111124235
Male324309633
08

Study locations

83 sites
  • Tokai Memorial Hospital
    Aichi, Kasugai, 487-0031, Japan
  • Japan Organization of Occupational Health and Safety Chubu Rosai Hospital
    Aichi, Nagoya, 455-8530, Japan
  • Tokuyama Clinic
    Chiba, Chiba, 261-0004, Japan
  • Matsuyama Shimin Hospital
    Ehime, Matsuyama, 790-0067, Japan
  • Tanaka Int. Clinic, Ehime, DIA Med.,CV Med.
    Ehime, Niihama, 792-0045, Japan
  • Murakami Memorial Hp., Ehime, I.M.
    Ehime, Saijo, 793-0030, Japan
  • Kunisaki Makoto Clinic, Fukuoka, I.M./CV Med.
    Fukuoka, Fukuoka, 819-0168, Japan
  • Fukuoka Shin Mizumaki Hospital
    Fukuoka, Onga, 807-0051, Japan
  • Shin Yukuhashi Hospital
    Fukuoka, Yukuhashi, 824-0026, Japan
  • Hashimoto I.M., Gifu, I.M.
    Gifu, Gifu, 500-8225, Japan
  • Kikuchi Naika Clinic, Gunma, I.M.
    Gunma, Maebashi, 370-3573, Japan
  • Hasegawa Internal Medicine Clinic
    Hokkaido, Chitose, 066-0032, Japan
  • Ebetsu Internal Medicine Clinic
    Hokkaido, Ebetsu, 067-0041, Japan
  • Hakodate Koseiin Hakodate Central General Hospital
    Hokkaido, Hakodate, 040-8585, Japan
  • Iida Medical Clinic
    Hokkaido, Hakodate, 042-0942, Japan
  • Kurihara Clinic
    Hokkaido, Sapporo, 004-0053, Japan
  • Uehara Clinic
    Hokkaido, Sapporo, 006-0031, Japan
  • Manda Memorial Hospital
    Hokkaido, Sapporo, 060-0062, Japan
  • Sapporo Diabetes, Thyroid Clinic
    Hokkaido, Sapporo, 060-0807, Japan
  • Japan Community Health Care Organization Hokkaido Hospital
    Hokkaido, Sapporo, 062-8618, Japan
  • Ashiya Municipal Hospital
    Hyogo, Ashiya, 659-8502, Japan
  • Itabashi DIA Med. and DERM Clinic, Ibaraki, I.M.
    Ibaraki, Koga, 306-0232, Japan
  • Namegata District General Hospital
    Ibaraki, Namegata, 311-3516, Japan
  • Hokuriku Hp., Ishikawa, I.M.
    Ishikawa, Kanazawa, 921-8035, Japan
  • Oikawa Clinic
    Iwate, Morioka, 020-0066, Japan
  • Hirano Medical Clinic
    Iwate, Morioka, 020-0132, Japan
  • Iwamoto Clinic, Kagawa, DIAB I.M.
    Kagawa, Zentsuji, 765-0071, Japan
  • Tenpozan Clinic of I.M., Kagoshima, I.M.
    Kagoshima, Kagoshima, 890-0061, Japan
  • Hayashi DIA Clinic, Kanagawa, DIA Tract Med.·I.M.
    Kanagawa, Chigasaki, 253-0044, Japan
  • Takai Naika Clinic
    Kanagawa, Kamakura, 247-0056, Japan
  • Nagatsuta Family Clinic, Kanagawa, I.M.
    Kanagawa, Yokohama, 226-0027, Japan
  • Motomachi Takatsuka Naika Clinic, Kanagawa, I.M.
    Kanagawa, Yokohama, 231-0023, Japan
  • Yokohama Minoru Clinic
    Kanagawa, Yokohama, 232-0064, Japan
  • Morinagaueno clinic, Kumamoto, Digestive Tract I.M.
    Kumamoto, Kumamoto, 860-0863, Japan
  • Kumamoto University Hospital
    Kumamoto, Kumamoto, 860-8556, Japan
  • Jinnouchi Clinic Diabetes Care Center
    Kumamoto, Kumamoto, 862-0976, Japan
  • Kajiyama Clinic, Kyoto, I.M.
    Kyoto, Kyoto, 615-0035, Japan
  • Matsumoto Nakagawa Hospital
    Nagano, Matsumoto, 399-0006, Japan
  • Ota DIA I.M. Clinic, Nagano, I.M.
    Nagano, Nagano, 380-0802, Japan
  • Saiseikai Niigata Daini Hp., Niigata, METAB ENDO
    Niigata, Niigata, 950-1104, Japan
  • Tsuyama Chuo Hospital
    Okayama, Tsuyama, 708-0841, Japan
  • Yaesu Clinic, Okinawa, I.M.
    Okinawa, Naha, 900-0032, Japan
  • Tanaka Clinic, Okinawa, I.M.
    Okinawa, Tomigusuku, 901-0244, Japan
  • Umeda Oak Clinic, Osaka, I.M.
    Osaka, Osaka, 530-0057, Japan
  • Kinugawa CARDIOL Clinic, Osaka, I.M.
    Osaka, Osaka, 532-0026, Japan
  • Ikeoka Clinic, Osaka, I.M.
    Osaka, Osaka, 536-0008, Japan
  • Nanko Clinic, Osaka, I.M.
    Osaka, Osaka, 559-0011, Japan
  • OCROM Clinic
    Osaka, Suita, 565-0853, Japan
  • AMC Nishi-umeda Clinic
    Osaka, 530-0001, Japan
  • Shiraiwa Medical Clinic, Osaka, I.M.
    Osaka, 582-0005, Japan
  • Saga Memorial Hospital
    Saga, Saga, 849-0917, Japan
  • Odayaka Life Naika Clinic, Saitama, I.M.
    Saitama, Koshigaya, 343-0828, Japan
  • Medical corporation Chisei-kai Watanabe clinic
    Saitama, Okegawa, 363-0022, Japan
  • Medical Corporation Toujinkai Sakado Central Hospital
    Saitama, Sakado, 350-0233, Japan
  • SAINO Clinic,
    Saitama, Tokorozawa, 359-1141, Japan
  • Hamamatsu Rosai Hospital
    Shizuoka, Hamamatsu, 430-8525, Japan
  • Plumeria Clinic, Shizuoka, I.M.
    Shizuoka, Shizuoka, 422-8006, Japan
  • Wakakusa Clinic, Tochigi, I.M.
    Tochigi, Shimotsuke, 329-0433, Japan
  • Nihonbashi Sakura Clinic
    Tokyo, Chuo-ku, 103-0025, Japan
  • Fukuwa Clinic
    Tokyo, Chuo-ku, 103-0027, Japan
  • Nihonbashi Enomoto Internal Medicine
    Tokyo, Chuo-ku, 103-0027, Japan
  • Tokyo-Eki Center-building Clinic
    Tokyo, Chuo-ku, 103-0027, Japan
  • Tokyo Center Clinic
    Tokyo, Chuo-ku, 103-0028, Japan
  • Hosono Clinic
    Tokyo, Chuo-ku, 104-0031, Japan
  • AGE Makita Medical Clinic
    Tokyo, Chuo-ku, 104-0061, Japan
  • Kasai Diabetes Clinic
    Tokyo, Edogawa-ku, 134-0084, Japan
  • New Medical Research System Clinic
    Tokyo, Hachioji, 192-0046, Japan
  • Medical Corporation Keikokai P1-Clinic
    Tokyo, Hachioji, 192-0071, Japan
  • Minamino Heart Clinic
    Tokyo, Hachioji, 192-0918, Japan
  • Shinkoiwa Ekimae Sougou Clinic
    Tokyo, Katushika-ku, 124-0024, Japan
  • Musashino Polyclinic
    Tokyo, Kiyose, 204-0021, Japan
  • Pedi Shiodome Clinic
    Tokyo, Minato-ku, 105-7390, Japan
  • Shinagawa East one Medical Clinic
    Tokyo, Minato-ku, 108-0075, Japan
  • Shimamura Kinen Hospital
    Tokyo, Nerima-ku, 177-0051, Japan
  • Kenkoukan Suzuki Clinic
    Tokyo, Ota-ku, 143-0015, Japan
  • Honda Hidehiko Clinic
    Tokyo, Ota-ku, 143-0023, Japan
  • Sakayori Clinic
    Tokyo, Shinagawa-ku, 140-0011, Japan
  • Miho Clinic
    Tokyo, Shinagawa-ku, 141-0032, Japan
  • ToCROM Clinic
    Tokyo, Shinjuku-ku, 160-0022, Japan
  • Ikebukuro Metropolitan Clinic
    Tokyo, Toshima-ku, 171-0021, Japan
  • Kanda Clinic, Tokyo, I.M.
    Tokyo, 101-0047, Japan
  • Fujikoshi Hp., Toyama, I.M.
    Toyama, Toyama, 930-0964, Japan
  • Clinic Sugiyama, Yamagata, I.M.
    Yamagata, Yamagata, 990-0885, Japan
09

References and documents

Publications

  • Kaku K, Haneda M, Tanaka Y, Lee G, Shiki K, Miyamoto Y, Solimando F, Lee J, Lee C, George J. Linagliptin as add-on to empagliflozin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two-part, randomized, placebo-controlled trial. Diabetes Obes Metab. 2019 Jan;21(1):136-145. doi: 10.1111/dom.13496. Epub 2018 Sep 6. PubMed 30091172 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2015 to primary completion in Nov 2016, 18 months.

Results were first posted in Sep 2018, 1 year 9 months after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 18 months is close to that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2015
First posted
Jul 3, 2015
StartActual
May 12, 2015
Primary completionActual
Nov 18, 2016
CompletionActual
Jun 16, 2017
Results first posted
Sep 6, 2018
Last update
Sep 6, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 6, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02489968
Responsible party
Sponsor
First posted
Jul 3, 2015
Start date
May 12, 2015
Primary completion
Nov 18, 2016
Completion
Jun 16, 2017
Results posted
Sep 6, 2018
Last update
Sep 6, 2018

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Empagliflozin

Start the discussion